Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 137

Sort by

Sort Order Select

Journal Articles

A Prospective, Multinational Study of Clinical and Biological Factors Associated with Short Overall Survival in Multiple Myeloma

Andy Tang, Kihyun Kim, Fiona Chen, Zoe K McQuilten, Peter Mollee, Rajeev Rajagopal, Hang Quach, Phoebe Joy Ho, Simon J. Harrison, Andrew Spencer, Wee-Joo Chng

Blood (2023) 142 (Supplement 1): 4731.

https://doi.org/10.1182/blood-2023-178192

Published: 2023

Journal Articles

Subgroup Analyses of Progression-Free Survival from the Phase 3 Octans and Alcyone Studies in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Bortezomib, Melphalan, and Prednisone with or without Daratumumab

Blood (2023) 142 (Supplement 1): 2006.

https://doi.org/10.1182/blood-2023-180809

Published: 2023

Journal Articles

Real-World Treatment Patterns, Outcomes, Health Care Resource Utilization and Cost Burden of Multiple Myeloma in South Korea Using the National Claims Data

YoungJu PARK, Sung Soo Park, Soomin Yoon, Jihyeon Jeong, Doik Lee, Kihyun Kim

Blood (2023) 142 (Supplement 1): 6672.

https://doi.org/10.1182/blood-2023-174019

Published: 2023

Journal Articles

Imaging Practices in Patients with Plasma Cell Dyscrasias across the Asian Myeloma Network - Survey Results and Recommendations

Natasha Fay Anthony, Wenming Chen, Chim James, Gin Gin Gan, Jeffrey Huang, Kihyun Kim, Teeraya Puavilai, Wee-Joo Chng, Kazuyuki Shimizu, Brian GM Durie, Chandramouli Nagarajan

Blood (2023) 142 (Supplement 1): 6666.

https://doi.org/10.1182/blood-2023-173228

Published: 2023

Journal Articles

Impact of 1q21 Gain and Amplification on Daratumumab-Treated Multiple Myeloma Patients: Real-World Data from the Australia-New Zealand and Asia-Pacific Myeloma and Related Diseases Registries

Kenneth J C Lim, Cameron Wellard, Elizabeth Moore, Slavisa Ninkovic, Wee-Joo Chng, Andrew Spencer, Peter Mollee, Jay Hocking, Phoebe Joy Ho, Wojt Janowski, Kihyun Kim, Karen Dun, Zoe K McQuilten, Fiona Chen, Hang Quach

Blood (2023) 142 (Supplement 1): 3325.

https://doi.org/10.1182/blood-2023-173896

Published: 2023

Journal Articles

Multicenter Prospective Phase II Study of Rituximab Combined, Bortezomib, Lenalidomide, Dexamethasone Followed By Lenalidomide Maintenance (R-VRD) in Patients with Waldenstrom's Macroglobulinemia (KMM1803)

Ho Sup Lee, Dajung Kim, Sung-Hoon Jung, Je-Jung Lee, Kihyun Kim, Chang-Ki Min, Jae Hoon Lee, Won-Sik Lee, JiHyun Lee, Gyeong Won Lee, Min Kyoung Kim, Ho-Jin Shin, Hyo Jung Kim, Jun Ho Yi

Blood (2023) 142 (Supplement 1): 2037.

https://doi.org/10.1182/blood-2023-180325

Published: 2023

Journal Articles

Cardiovascular Toxicity after Carfilzomib, Lenalidomide, and Dexamethasone Combination Chemotherapy in the Real-World 364 Asian Multiple Myeloma Patients on Behalf of the Korean Multiple Myeloma Working Party (KMM2201 study)

Blood (2023) 142 (Supplement 1): 6675.

https://doi.org/10.1182/blood-2023-174439

Published: 2023

Journal Articles

Daratumumab, Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Asian Patients with Newly Diagnosed Multiple Myeloma: Final Analysis of the Phase 3 Octans Study

Weijun Fu, Soo-Mee Bang, Honghui Huang, Kihyun Kim, Wei Li, Gang An, Je-Jung Lee, Zhen Cai, Jie Jin, Yafei Wang, Chor Sang Chim, Robin Carson, Rui Liu, Lingling Wang, Man Zhao, Xi Chen, Canchan Cui, Jian Hou, Jianxiang Wang

Blood (2023) 142 (Supplement 1): 3388.

https://doi.org/10.1182/blood-2023-181063

Published: 2023

Journal Articles

Personal Financial Burdens of Multiple Myeloma: A Deep Dive into the Patient's Journey Using Qualitative Interview

YoungJu PARK, Juhee Cho, Sooyeon Kim, Kihyun Kim, Sang Eun Yoon, Danbee Kang, Garam Bang, Nayeon Kim, Jeong Hyun Park, Seok Jin Kim

Blood (2023) 142 (Supplement 1): 5088.

https://doi.org/10.1182/blood-2023-178418

Published: 2023

Journal Articles

Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial

Paul G. Richardson, Suzanne Trudel, Hang Quach, Rakesh Popat, Sagar Lonial, Robert Z. Orlowski, Kihyun Kim, María-Victoria Mateos, Charlotte Pawlyn, Karthik Ramasamy, Joaquín Martinez-Lopez, Alessia Spirli, Ignacio Casas-Avilés, Jing Gong, Michael Amatangelo, Jessica Katz, Paulo Maciag, Teresa Peluso, Nizar J. Bahlis

Blood (2022) 140 (Supplement 1): 1366–1368.

https://doi.org/10.1182/blood-2022-157945

Published: 2022

Journal Articles

Carfilzomib Use Among Patients with Relapsed/Refractory Multiple Myeloma in the Asia Pacific Region: Characteristics and Outcomes By Regimen from a Prospective, Real-World Study

Hang Quach, Sung-Soo Yoon, Kihyun Kim, Ji Hyun Lee, Chandramouli Nagarajan, Phoebe Joy Ho, Michael S.Y. Low, Wei-Han Huang, Raymond Wong, Nina Liao, ChingFeng Lin, Matthew Britland, Julia Li, Stella Chai, Jin Seok Kim

Blood (2022) 140 (Supplement 1): 4264–4266.

https://doi.org/10.1182/blood-2022-159324

Published: 2022

Journal Articles

Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study

Blood (2021) 138 (Supplement 1): 159.

https://doi.org/10.1182/blood-2021-146820

Published: 2021

Journal Articles

Real-World Effectiveness of Bortezomib Plus Dexamethasone in Patients with t(11;14) Positive Multiple Myeloma

Nnadozie Emechebe, Shaji Kumar, Hartmut Goldschmidt, Maria-Victoria Mateos, Juan Du, Kihyun Kim, Giampaolo Merlini, Meletios A. Dimopoulos, Heinz Ludwig, Hiroshi Handa, Carlos Fernandez de Larrea, Donna E. Reece, Wenming Chen, Noopur S. Raje, Sudeep Karve, Emma Arriola, Jeremy A. Ross, Brian G.M. Durie

Blood (2021) 138 (Supplement 1): 4725.

https://doi.org/10.1182/blood-2021-149270

Published: 2021

Journal Articles

Health-Related Quality of Life and Symptoms Among Patients with Relapsed or Refractory AL Amyloidosis Treated with Ixazomib-Dexamethasone Versus Physician's Choice: Results from a Randomized Phase 3 Trial

Vaishali Sanchorawala, Ashutosh D. Wechalekar, Kihyun Kim, Stefan Schönland, Heather J Landau, Kwok Fiona, Kenshi Suzuki, Angela Dispenzieri, Giampaolo Merlini, Raymond Comenzo, Dasha Cherepanov, Vanessa C Hayden, Arun Kumar, Richard Labotka, Douglas V. Faller, Efstathios Kastritis

Blood (2021) 138 (Supplement 1): 4771.

https://doi.org/10.1182/blood-2021-148689

Published: 2021

Journal Articles

Results of an International, Multi-Centre, Retrospective Study to Describe Treatment Pathways, Outcomes and Resource Use in Patients with Multiple Myeloma in Emerging Markets (INTEGRATE)

Kihyun Kim, Natalia Paola Schutz, Su-Peng Yeh, Estelle Verburgh, Fahad Alsharif, Wenming Chen, Tatiana Mitina, Wee-Joo Chng, Cathy Wu, Hui Wan, Zhongwen Huang, Meral Beksac

Blood (2021) 138 (Supplement 1): 3045.

https://doi.org/10.1182/blood-2021-147108

Published: 2021

Journal Articles

Daratumumab, Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: Pooled Analysis of Octans and Alcyone

Blood (2021) 138 (Supplement 1): 1661.

https://doi.org/10.1182/blood-2021-146974

Published: 2021

Journal Articles

Progression-Free Survival Outcomes By Response Status for Bortezomib, Melphalan, and Prednisone with or without Daratumumab in Newly Diagnosed Multiple Myeloma: Pooled Subgroup Analysis of Octans and Alcyone

Blood (2021) 138 (Supplement 1): 1648.

https://doi.org/10.1182/blood-2021-148937

Published: 2021

Journal Articles

Exploration of the Appropriate NT-Probnp Level for AL Amyloidosis Staging

Hana Kim, Darae Kim, Jinoh Choi, Eunseok Jeon, Jung Eun Lee, Ju Hong Min, Joon Young Choi, Jung-Sun Kim, Seokjin Kim, Kihyun Kim

Blood (2021) 138 (Supplement 1): 3777.

https://doi.org/10.1182/blood-2021-151675

Published: 2021

Journal Articles

Development of a New Risk Stratification System for Patients with Newly Diagnosed Multiple Myeloma Using R-ISS and 18F-FDG PET/CT

Blood (2021) 138 (Supplement 1): 3757.

https://doi.org/10.1182/blood-2021-152008

Published: 2021

Journal Articles

Subcutaneous Daratumumab (DARA SC) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Asian Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Subgroup Analysis from the Phase 3 Andromeda Study

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-136150

Published: 2020

NARROW

A Prospective, Multinational Study of Clinical and Biological Factors Associated with Short Overall Survival in Multiple Myeloma

Subgroup Analyses of Progression-Free Survival from the Phase 3 Octans and Alcyone Studies in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Bortezomib, Melphalan, and Prednisone with or without Daratumumab

Real-World Treatment Patterns, Outcomes, Health Care Resource Utilization and Cost Burden of Multiple Myeloma in South Korea Using the National Claims Data

Imaging Practices in Patients with Plasma Cell Dyscrasias across the Asian Myeloma Network - Survey Results and Recommendations

Impact of 1q21 Gain and Amplification on Daratumumab-Treated Multiple Myeloma Patients: Real-World Data from the Australia-New Zealand and Asia-Pacific Myeloma and Related Diseases Registries

Multicenter Prospective Phase II Study of Rituximab Combined, Bortezomib, Lenalidomide, Dexamethasone Followed By Lenalidomide Maintenance (R-VRD) in Patients with Waldenstrom's Macroglobulinemia (KMM1803)

Cardiovascular Toxicity after Carfilzomib, Lenalidomide, and Dexamethasone Combination Chemotherapy in the Real-World 364 Asian Multiple Myeloma Patients on Behalf of the Korean Multiple Myeloma Working Party (KMM2201 study)

Daratumumab, Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Asian Patients with Newly Diagnosed Multiple Myeloma: Final Analysis of the Phase 3 Octans Study

Personal Financial Burdens of Multiple Myeloma: A Deep Dive into the Patient's Journey Using Qualitative Interview

Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial

Carfilzomib Use Among Patients with Relapsed/Refractory Multiple Myeloma in the Asia Pacific Region: Characteristics and Outcomes By Regimen from a Prospective, Real-World Study

Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study

Real-World Effectiveness of Bortezomib Plus Dexamethasone in Patients with t(11;14) Positive Multiple Myeloma

Health-Related Quality of Life and Symptoms Among Patients with Relapsed or Refractory AL Amyloidosis Treated with Ixazomib-Dexamethasone Versus Physician's Choice: Results from a Randomized Phase 3 Trial

Results of an International, Multi-Centre, Retrospective Study to Describe Treatment Pathways, Outcomes and Resource Use in Patients with Multiple Myeloma in Emerging Markets (INTEGRATE)

Daratumumab, Bortezomib, Melphalan, and Prednisone Versus Bortezomib, Melphalan, and Prednisone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma: Pooled Analysis of Octans and Alcyone

Progression-Free Survival Outcomes By Response Status for Bortezomib, Melphalan, and Prednisone with or without Daratumumab in Newly Diagnosed Multiple Myeloma: Pooled Subgroup Analysis of Octans and Alcyone

Exploration of the Appropriate NT-Probnp Level for AL Amyloidosis Staging

Development of a New Risk Stratification System for Patients with Newly Diagnosed Multiple Myeloma Using R-ISS and 18F-FDG PET/CT

Subcutaneous Daratumumab (DARA SC) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Asian Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Subgroup Analysis from the Phase 3 Andromeda Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only